When was Veralox Therapeutics founded?

Veralox Therapeutics was founded in 2017 and raised its 1st funding round 1 year after it was founded.

Where is Veralox Therapeutics located?

Veralox Therapeutics is headquartered in Frederick, United States.

How many employees does Veralox Therapeutics have?

As of Dec 31, 2021, Veralox Therapeutics has 6 employees, reflecting a 100% year-over-year growth in headcount.

Is Veralox Therapeutics a funded company?

Veralox Therapeutics is a funded company, having raised a total of $47.5M across 6 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Sep 07, 2018.

When was the latest funding round of Veralox Therapeutics?

Veralox Therapeutics' latest funding was a $***** Series B round on Jun 21, 2023, with participation from 6 investors. Its primary sector is Diabetes. In United States, the Diabetes sector has seen $490M in funding in 2026 to date.

Where does Veralox Therapeutics rank among its competitors?

Veralox Therapeutics ranks 84th amongst 2707 active competitors, of which 934 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Veralox Therapeutics?

Veralox Therapeutics' top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Among them, Immuneel secured the most recent funding round in June, 2026.

Veralox Therapeutics - 2026 Company Profile, Team, Funding & Competitors

Veralox Therapeutics is a series B company based in Frederick (United States), founded in 2017 by David Maloney. It operates as a Developer of small molecules for treating thrombosis and diabetes pathologies. Veralox Therapeutics has raised $47.5M in funding from investors like Hatteras Venture Partners, VTC Innovation Fund and T1D Fund. The company has 2707 active competitors, including 934 funded and 665 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences.

Company Details

Veralox Therapeutics is developing small molecule therapeutics for targeting pathways related to the pathologies of thrombosis and type 1 diabetes. The company is developing small molecules to target arachidonic acid (AA) pathway protein 12-lipoxygenase required for the production of 12-HETE involved in the development of multiple diseases.

Website: veralox.com
Email ID: *****@veralox.com
Phone Number: +1 **********

Key Metrics

Founded Year

2017

Location

Frederick, United States

Stage

Series B

Total Funding

$47.5M in 6 rounds

Latest Funding Round

Series B, Jun 21, 2023, $*****

Investors

Hatteras Venture Partners & 14 more

Ranked

84^th among 2707 active competitors

Employee Count

6 as on Dec 31, 2021

Similar Companies

Sana Biotechnology & 391 more

View Veralox Therapeutics' full profile

Veralox Therapeutics is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
VERALOX THERAPEUTICS INC. CIN: 82-3072071 , United States, Active	May 03, 2018	-	6 (As on Dec 31, 2021)	-

Veralox Therapeutics has raised a total funding of $47.5M over 6 rounds. Its first funding round was on Sep 07, 2018. Its latest funding round was a Series B round on Jun 21, 2023 for $*****. 6 investors participated in its latest round. Veralox Therapeutics has 15 institutional investors.

Here is the list of recent funding rounds of Veralox Therapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 21, 2023	4771271	Series B	1605576	2235083	6998285	9827369
Jun 16, 2021	5589007	Series A	5816212	1459275	1224680	Genesys Capital & 7 more
Jan 01, 2020	5810993	Grant (prize money)	1798230	9226777	7802622	HHS

Access funding benchmarks and valuations. Sign up today!

View details of Veralox Therapeutics's funding rounds and investors

The founders of Veralox Therapeutics is David Maloney.

Here are the details of Veralox Therapeutics' key team members:

David Maloney: Co-Founder of Veralox Therapeutics and founder of 1 other company.
Contact Info: 1 email address

View details of Veralox Therapeutics's Founder profiles and Board Members

Veralox Therapeutics' employee count trend

Veralox Therapeutics has 6 employees as of Dec 21. The total employee count is 100.0% more than what it was in Dec 20. Here is Veralox Therapeutics's employee count trend over the years:

Employee count trend for Veralox Therapeutics

Uncover Veralox Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Veralox Therapeutics include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Here is the list of Top 10 competitors of Veralox Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, F-Prime Capital & 17 others	74/100
3rd	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
4th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
5th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Domain Associates, Fidelity Investments & 19 others	72/100
6th	Karyopharm 2008, Newton (United States), Public	Biopharmaceutical company focused on developing and commercializing innovative cancer therapies	$98.4M	Foresite Capital, Avidity Partners & 16 others	72/100
7th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	71/100
8th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
9th	Zymeworks 2003, Vancouver (Canada), Public	Developer of bi-specific antibodies & antibody-drug conjugates to treat cancer	$146M	CTI Life Sciences Fund, Advanced Biotechnologies Venture Fund ... & 17 others	71/100
10th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
84th	Veralox Therapeutics 2017, Frederick (United States), Series B	Developer of small molecules for treating thrombosis and diabetes pathologies	$47.5M	Sanofi Ventures, TEDCO & 13 others	63/100